Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

tags : Pharm-country    save search

Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine
Published: 2023-02-08 (Crawled : 23:00) - biospace.com/
CARA S | $11.67 -2.26% -2.31% 170K twitter stocktwits trandingview |
Health Technology
| | O: 1.01% H: 1.92% C: -2.67%

treatment pruritus for trial therapeutics results
Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments
Published: 2023-02-08 (Crawled : 17:00) - biospace.com/
OVID | $2.4 -5.14% -7.2% 110K twitter stocktwits trandingview |
Health Technology
| | O: 4.6% H: 0.8% C: -4.0%

therapeutics
BioXcel Therapeutics to Host BXCL701 Key Opinion Leader Day to Highlight Company’s Investigational, Oral Innate Immune Activator for Rare Form of Prostate Cancer
Published: 2023-02-08 (Crawled : 15:00) - biospace.com/
BTAI | $33.24 8.31% 7.62% 730K twitter stocktwits trandingview |
Health Technology
| | O: 5.06% H: 6.5% C: 5.39%

bxcl701 day rare for therapeutics cancer
BD Receives FDA Emergency Use Authorization for COVID-19, Influenza A/B, RSV Combination Test
Published: 2023-02-08 (Crawled : 15:00) - biospace.com/
BDX S | $250.23 -1.17% 0.0% 1.1M twitter stocktwits trandingview |
Health Technology
| | O: 1.06% H: 0.0% C: 0.0%

covid-19 fda for test rsv authorization influenza
BioRestorative Therapies Announces Notice of Allowance by the European Patent Office for Patent Related to its ThermoStem® Program
Published: 2023-02-08 (Crawled : 15:00) - biospace.com/
BRTX | $3.0 -0.35% 1.94% 52K twitter stocktwits trandingview |
Professional, Scientific, and T...
| | O: -1.3% H: 7.89% C: -1.32%

thermostem patent for program
Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas
Published: 2023-02-08 (Crawled : 13:00) - biospace.com/
IPSC A | $4.65 -2.31% -2.15% 110K twitter stocktwits trandingview |
Professional, Scientific, and T...
| | O: 4.53% H: 1.03% C: -4.12%

cnty-101 lymphomas cd19 trial therapeutics positive
Outlook Therapeutics® to Present at the SVB Securities Global Biopharma Conference– Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics to present on Tuesday, February 14th at 4:20 PM ET –
Published: 2023-02-07 (Crawled : 15:00) - biospace.com/
OTLK | $1.27 0.0% 470K twitter stocktwits trandingview |
Health Technology
| | O: 8.9% H: 0.0% C: 0.0%

therapeutics biopharma global
BioSig Appoints Former Qorvo CFO as Successor to Steve Chaussy
Published: 2023-02-07 (Crawled : 15:00) - biospace.com/
BSGM P 349323 | $1.17 2.63% 2.56% 260K twitter stocktwits trandingview |
Health Technology
| | O: 1.71% H: 0.0% C: 0.0%

qorvo
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
Published: 2023-02-07 (Crawled : 13:00) - biospace.com/
MRNS S | $7.25 8.05% 7.32% 860K twitter stocktwits trandingview |
Health Technology
| | O: -1.52% H: 0.0% C: 0.0%

pharmaceuticals
Hyperfine Swoop® Point-of-Care MRI System™ Takes the Stage at ISMRM with Twelve Abstract InclusionsResearch highlights the significance and clinical relevance of portable MRI technology
Published: 2023-02-06 (Crawled : 01:00) - biospace.com/
HYPR | $1.22 8.93% 7.44% 280K twitter stocktwits trandingview |
Manufacturing
| | O: 10.26% H: 0.0% C: 0.0%

swoop technology
Seelos Therapeutics Doses First Patients in an Ethnobridging Study with SLS-002 (Intranasal Racemic Ketamine)
Published: 2023-02-06 (Crawled : 15:00) - biospace.com/
SEEL | $0.8002 -6.95% -7.17% 440K twitter stocktwits trandingview |
Health Technology
| | O: -4.36% H: 6.01% C: 6.01%

sls-002 therapeutics study
Janssen Reports Positive Topline Phase 2 Results for Nipocalimab in Pregnant Individuals at High Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
Published: 2023-02-06 (Crawled : 15:00) - biospace.com/
JNJ | $163.61 0.13% 0.15% 4.7M twitter stocktwits trandingview |
Health Technology
| | O: -0.75% H: 0.0% C: 0.0%

risk disease for topline positive results
ProPhase Labs Provides Update on Linebacker-1 Cancer Co-Therapy Program and Outlines Development Strategy
Published: 2023-02-06 (Crawled : 15:00) - biospace.com/
PRPH | $8.14 -0.85% -1.23% 40K twitter stocktwits trandingview |
Health Technology
| | O: 3.82% H: 0.0% C: -6.29%

program update cancer
Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference
Published: 2023-02-03 (Crawled : 14:20) - biospace.com/
BMY S | $73.65 -1.17% 0.03% 7.9M twitter stocktwits trandingview |
Health Technology
| | O: 0.65% H: 0.0% C: 0.0%

conference
Tonix Pharmaceuticals to Participate in BIO CEO & Investor Conference - February 3, 2023
Published: 2023-02-03 (Crawled : 14:20) - biospace.com/
TNXP | $1.23 4.24% 2.48% 4M twitter stocktwits trandingview |
Health Technology
| | O: 6.9% H: 0.0% C: 0.0%

pharmaceuticals ceo conference
PaxMedica, Inc. Secures $3.2 Million Growth Capital From Lind Partners
Published: 2023-02-03 (Crawled : 14:20) - biospace.com/
PXMD | $3.3 -8.84% -10.03% 600K twitter stocktwits trandingview |
Health Technology
| | O: 17.42% H: 0.0% C: 0.0%

growth
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma
Published: 2023-02-03 (Crawled : 14:20) - biospace.com/
MRK S | $106.64 0.91% 0.16% 6.7M twitter stocktwits trandingview |
Health Technology
| | O: -0.31% H: 0.0% C: 0.0%

keytruda for plus therapy
Cigna Reports Strong Fourth Quarter and Full Year 2022 Results, Establishes 2023 Guidance and Increases Dividend
Published: 2023-02-03 (Crawled : 12:20) - biospace.com/
CI G | $290.2 0.42% 0.0% 2M twitter stocktwits trandingview |
Health Services
| | O: -1.82% H: 0.0% C: 0.0%

dividend year
Y-mAbs and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for Naxitamab
Published: 2023-02-02 (Crawled : 16:00) - biospace.com/
YMAB | $4.28 -4.89% -5.14% 220K twitter stocktwits trandingview |
Health Technology
| | O: 2.64% H: 4.29% C: 3.43%

for agreement
Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
Published: 2023-02-02 (Crawled : 14:00) - biospace.com/
MRK S | $106.64 0.91% 0.16% 6.7M twitter stocktwits trandingview |
Health Technology
| | O: -2.83% H: 1.72% C: -0.54%
SGEN S | $136.89 -0.4% -0.49% 620K twitter stocktwits trandingview |
Health Technology
| | O: -0.47% H: 1.07% C: 0.66%
SNY | $47.71 1.58% 1.57% 2M twitter stocktwits trandingview |
Health Technology
| | O: -1.44% H: 0.0% C: 0.0%
MRNA M | $164.34 -3.93% -4.09% 2.4M twitter stocktwits trandingview |
Health Technology
| | O: -0.82% H: 1.92% C: 1.7%

financial results
Gainers vs Losers
57% 43%

Top 10 Gainers
CZOO | $0.2001 -16.63% 1839.03% 3.3M twitter stocktwits trandingview |

CELZ | $1.04 101.04% 50.26% 140M twitter stocktwits trandingview |

AVRO | $1.69 93.7% 47.75% 38M twitter stocktwits trandingview |
Health Technology

HPCO | $0.755 -6.05% 37.22% 3.4M twitter stocktwits trandingview |

SASI 4 | $0.6615 -2.72% 11.87% 10K twitter stocktwits trandingview |
Manufacturing

RAAS | $0.8897 0.62% 11.27% 400K twitter stocktwits trandingview |
Information

VNTR | $0.64 1.59% 10.63% 390K twitter stocktwits trandingview |
Process Industries

NYMX | $0.4346 0.98% 9.76% 29K twitter stocktwits trandingview |
Health Technology

PLAG 4 | $0.5922 -2.12% 9.76% 9.8K twitter stocktwits trandingview |
Consumer Non-Durables

ICU | $4.8 3.67% 9.22% 1.2M twitter stocktwits trandingview |


Your saved searches
Save your searches and get alerts when important news are released.